SOLICITATION NOTICE
99 -- Terminal Extension of Contract
- Notice Date
- 5/28/2002
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-20051-NG
- Response Due
- 6/12/2002
- Archive Date
- 6/27/2002
- Point of Contact
- Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
- E-Mail Address
-
holdcram@exchange.nih.gov, rasmusc@mail.nih.gov
- Description
- The National Cancer Institute (NCI), Laboratory of Experimental Carcinogenesis (LEC) plans to procure continuing services relating to the "Cellular and Molecular Studies of Human Hepatocarcinogenesis in China" study at the Chinese Academy of Medical Sciences, Cancer Institute, Panjiayuan, Beijing 100021 Peoples Republic of China. The North American Industry Classification System code is 541990 and the business size standard is $5M. Human hepatocellular carcinoma (HCC) is one of the most common cancers in Asia and Africa. Hepatitis B virus (HBV) has been identified as the major causative agent of HCC in endemic countries such as China. However, epidemiological evidence indicates that other factors, including hepatitis C, heredity, and the mycotoxin aflatoxin B1 may also play an important role in the development of hepatocarcinogenesis. In both Beijing and Qidong County of the People's Republic of China, there is a high incidence of chronic hepatitis B infection and hepatocellular carcinoma. While the denizens of Beijing have a low exposure to aflatoxin B1, those living in Qidong are exposed to high levels of aflatoxin B1 from their dietary intake of contaminated foods. There is evidence to suggest that middle-aged male carriers in Qidong may be 2-3 times more at risk to develop HCC than their counterparts in Beijing. The unique and long standing cooperation between the Chinese Academy of Medical Sciences and the Liver Cancer Institute at the Qidong County provides a combination of rare expertise in clinical as well as in basic science aspects of liver cancer in addition to access to a unique population of high risk individuals for both chronic hepatitis and hepatocellular carcinoma. These unique qualifications, as well as the progress and success that has already been encountered during the previous pilot study under contract N01-CP-15618 and the recent follow-on contracts N02-BC-40538 and N02-BC-81021. This study will continue to provide unique research opportunities illustrated in the following: 1) is an increase in serum a-fetoprotein (AFP) with a low and fluctuating pattern predictive of a biostatistically significant risk for subsequent development of hepatocellular carcinoma among carriers and; 2) the ability of a considerable number of surgical specimens (30 samples per year) and case history records, in addition to serum samples take exposure to aflatoxin B1 is associated with increased allelic losses and possibly selective allelic losses during the development of HCC. In these studies, HCC's from both Beijing and Qidong have been examined for mutations in p53. The purpose of this study is to test the hypothesis that exposure to aflatoxin B1 is associated with increased allelic losses and possibly selective allelic losses during the development of HCC. In this study, HCC will be examined for mutations in p53, and for loss of heterozygosity for p53, RB, and APC genes and at marker loci on chromosomes 4, 13, and 16. The Chinese Academy of Medical Sciences, Cancer Institute is the only source that can provide the above service. Changing variables at this time will interrupt correct interpretation of experiment in progress. This notice of intent is not a request for competitive quotation. However, if any interested party believes it can meet the above requirements, it may submit a statement of capabilities. The capability statement and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can fully meet the requirements herein. Capability statements must be received in the contracting office by 1:00 PM EDT (local Washington, D.C. time) on June 12, 2002. If you have any questions, please submit them via electronic mail to Malinda Holdcraft, Purchasing Agent at holdcram@exchange.nih.gov or by fax at 301-402-4513. A determination by the Government not to compete this proposed requirement based on responses to this notice is solely withing the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed copies of capability statements will be accepted. If submitting capability statements, one (1) original and two (2) copies must be mailed to: Malinda Holdcraft Purchasing Agent, NIH/NCI/RCB, 6120 Executive Blvd. Suite 6072, Rockville Maryland, 20892.
- Place of Performance
- Address: NCI/NCI, 9000 Rockville Pike, Bethesda, MD
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN00083944-W 20020530/020528213223 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |